Covance Company Profile (NYSE:CVD)

Analyst Ratings

Consensus Ratings for Covance (NYSE:CVD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Covance (NYSE:CVD)
Show:
DateFirmActionRatingPrice TargetActions
11/7/2014Jefferies GroupDowngradeBuy -> Hold$98.00 -> $104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014KeyCorpDowngradeBuy -> Hold$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014William BlairDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$97.00 -> $103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Robert W. BairdDowngradeOutperform -> Neutral$99.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014Piper Jaffray Cos.DowngradeOverweight -> Neutral$99.00 -> $103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/14/2014Bank of America Corp.Reiterated RatingNeutral$95.00 -> $88.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014SunTrust Banks Inc.Reiterated RatingNeutral$89.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Covance (NYSE:CVD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/4/2015Q414$0.96$0.97$631.30 million$634.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314$0.98$0.98$651.00 million$627.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$0.93$0.95$639.80 million$687.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$0.90$0.90$632.01 million$620.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$0.84$0.87$613.80 million$623.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$0.80$0.83$594.30 million$606.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013$0.77$0.78$586.12 million$644.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.72$0.75$569.34 million$580.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2013Q4 2012$0.71$0.73$548.84 million$562.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312$0.67$0.72$546.52 million$597.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2012$0.64$0.65ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012$0.60$0.68ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2012$0.73$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011$0.70$0.71ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.65$0.66ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.58$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2011$0.53$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Covance (NYSE:CVD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Covance (NYSE:CVD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Covance (NYSE:CVD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/22/2014Brian H NuttInsiderSell1,127$103.51$116,655.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Joseph L HerringCEOSell32,692$103.02$3,367,929.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014John E WatsonVPSell15,200$102.94$1,564,688.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Joseph L HerringCEOSell32,200$85.13$2,741,186.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014James LovettVPSell14,955$102.47$1,532,438.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Brian NuttInsiderSell1,808$100.12$181,016.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Richard CiminoEVPSell13,000$99.10$1,288,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Sandra HeltonDirectorSell2,800$99.03$277,284.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Richard CiminoEVPSell16,000$84.86$1,357,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Sandra L HeltonDirectorSell3,000$81.92$245,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013William E KlitgaardVPSell25,323$81.44$2,062,305.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Deborah KellerEVPSell15,900$83.12$1,321,608.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Robert BarchiDirectorSell13,667$82.78$1,131,354.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Gary CostleyDirectorSell7,467$82.77$618,043.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Joseph HerringCEOSell100,000$82.54$8,254,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Joseph L HerringCEOSell13,259$77.00$1,020,943.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Joseph L HerringCEOSell22,391$78.03$1,747,169.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013James W LovettVPSell10,259$77.00$789,943.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Covance (NYSE:CVD)
DateHeadline
06/21/16 06:00 AMLabCorp Sees Balanced Growth; Covance Synergy on Track -
06/02/16 10:00 AMLaboratory Corp. of America Looks Pretty Healthy -
05/17/16 07:07 AMLabCorp (LH) Posts Strong Q1; Covance Synergy Continues -
05/08/16 06:05 AMEarly Development, Central Labs Businesses: Strong Demand in 1Q16 -
05/03/16 06:14 AMINC Research Holdings In The Spotlight As Rumors Of A Suitor Circulate - INC Research Holdings (NASDAQ ... are going to be excellent in the next year with targets in both diagnostics and contract research." Covance (NYSE:CVD) was acquired by LabCorp last year for $6.1 billion. A Double Win King, said, "the priority for Covance ...
04/29/16 06:57 AMAbbott Laboratories Acquisition - Cardiovascular medical devices are important tools to address the growing health and economic burden of cardiovascular disease (>> Covance Inc.). In the U.S. alone, more than 40 percent of adults are expected to have one or more forms of CVD by 2030.
04/25/16 09:02 AMLabCorp (LH) Tops Q1 Earnings and Sales, Raises Guidance -
04/19/16 10:00 AMTesting LabCorp's Deal Plans -
04/11/16 09:41 AMLabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development - [at noodls] - BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 11, 2016-- Laboratory Corporation of America Holdings (LabCorp) (NYSE:LH) today announced that Jonathan Zung, Ph.D., has been named group president, Clinical Development ...
02/23/16 03:13 PMLabCorp (LH): Revenues Strong on Balanced Organic Growth -
02/18/16 12:00 PMLabCorp's King: 2015 was 'transformative' -
02/18/16 10:02 AMLabCorp Q4 Earnings Miss, Revenues Top; Currency Bothers -
02/18/16 06:45 AMLabCorp Tops Revenues, Misses on Earnings in Q4 -
02/15/16 12:00 PMWill LabCorp (LH) Disappoint Earnings Estimates in Q4? -
01/05/16 01:35 PMLabCorp Poised on Strategic Initiatives, Currency Woes Linger -
12/01/15 01:15 PMLabCorp (LH) Posts Mixed Q3, Covance Synergy on Track -
10/28/15 07:17 PMNeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services - [at noodls] - FT. MYERS, Fla., Oct. 28, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an amended Strategic Alliance Agreement with ...
10/26/15 02:57 PMLaboratory Corp. of America (LH) Stock Gains on Earnings Beat -
10/26/15 01:00 PMCovance deal continues to fuel revenue, earnings growth for LabCorp -
10/26/15 08:50 AMLabCorp Q3 Earnings in Line, Revenues Strong; View Revised -
10/26/15 07:10 AMLabCorp (LH) Q3 Earnings in Line, Revenues Beat Estimates -
10/26/15 06:51 AM[$$] LabCorp's Sales Soars Following Covance Buy -
10/23/15 01:20 PMLabCorp expands beyond labwork with purchase of food and beverage company -
09/21/15 03:35 PMCovance to Open Second Current Good Manufacturing Practice (cGMP) Pharmacy in U.S. - [at noodls] - Covance is the only CRO to offer cGMP manufacturing in a U.S. Phase I Clinical Research Unit BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ...
07/28/15 04:39 PMLaboratory Corp Of America (LH) Earnings Report: Q2 2015 Conference Call Transcript -
07/28/15 06:56 AMLabCorp Announces New Covance Leadership - [at noodls] - Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced ...
07/24/15 01:25 PMWill LabCorp (LH) Keep its Earnings Streak Alive in Q2? - Analyst Blog -
07/23/15 07:50 AMCovance Opens Fit-for-Purpose Dallas Clinical Research Unit - [at noodls] - LabCorp patient service center to be co-located in new facility to serve local patients and enhance volunteer recruitment DALLAS--(BUSINESS WIRE)--Jul. 23, 2015-- Laboratory Corporation of America® Holdings ...
06/16/15 09:45 AMKeyBanc Starts Lab Corp Of America At Overweight, But Indebtedness Is A Concern -
06/02/15 08:29 AMLabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference - [at noodls] - BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Goldman Sachs 36th Annual Global Healthcare ...

Social

About Covance

Covance logoCovance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Life Sciences Tools & Services
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: CVD
  • CUSIP: 22281610
Key Metrics:
  • Previous Close: $106.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $92
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $4 EPS
  • Next Year EPS Consensus Estimate: $5 EPS
Additional Links:
Covance (NYSE:CVD) Chart for Tuesday, July, 26, 2016